Atria Investments Inc Has $40.30 Million Position in Johnson & Johnson (NYSE:JNJ)

Atria Investments Inc boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 17.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 243,026 shares of the company's stock after purchasing an additional 36,766 shares during the period. Johnson & Johnson accounts for approximately 0.5% of Atria Investments Inc's holdings, making the stock its 27th largest holding. Atria Investments Inc's holdings in Johnson & Johnson were worth $40,303,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of JNJ. Geode Capital Management LLC boosted its position in shares of Johnson & Johnson by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after purchasing an additional 1,561,036 shares during the last quarter. Northern Trust Corp boosted its position in shares of Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after purchasing an additional 3,363,235 shares during the last quarter. Norges Bank bought a new position in shares of Johnson & Johnson in the 4th quarter worth $4,390,037,000. Wellington Management Group LLP boosted its position in shares of Johnson & Johnson by 1.8% in the 4th quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock worth $3,522,447,000 after purchasing an additional 431,205 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 0.7%

Shares of NYSE:JNJ traded down $1.27 during midday trading on Friday, reaching $168.29. The company had a trading volume of 6,199,690 shares, compared to its average volume of 8,375,731. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The business's 50 day moving average price is $156.08 and its 200 day moving average price is $155.78. The stock has a market cap of $404.92 billion, a PE ratio of 18.00, a P/E/G ratio of 2.16 and a beta of 0.41. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.82 EPS. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.09%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Royal Bank Of Canada raised their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday. Guggenheim reissued a "neutral" rating and issued a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Raymond James Financial decreased their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.